HIV Scientific Papers
Predictors of Prevalence and Reduction of VAT in HIV-Infected Patients.
2012
Hayward B, Stanworth S, Stepanians M, Mangili A.
Poster #P012 presented at: 14th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; July 19-21 2012; Washington, DC, USA.
Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.
2012
J Clin Endocrinol Metab.
Makimura H, Feldpausch MN, Rope AM, et al.
97(12):4769-4779.
Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.
2012
Arch Neurol.
Baker LD, Barsness SM, Borson S, et al.
69(11):1420-1429.
Impact of tesamorelin, a growth hormone‐releasing factor (GRF) analogue, on the pharmacokinetics of simvastatin and ritonavir in healthy volunteers.
2012
Clin Pharmacol Drug Dev.
Teng S, Potvin D, Mamputu J-C, et al.
2(3):237-245.
Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.
2012
Clin Infect Dis.
Stanley TL, Falutz J, Marsolais C, et al.
54(11):1642-1651.